Background: Taxanes are an established treatment of metastatic breast cancer (mBC). Biological therapies that can be effectively combined with taxanes may provide an alternative to taxane-chemotherapy doublets, which are not suitable for all patients.
introduction taxanes in the treatment of metastatic breast cancer
The role of taxanes is well established in the treatment of advanced breast cancer, with their use recommended by USA and European Union (EU) guidelines and a recent consensus manuscript [1] [2] [3] . The activity of taxanes in the first-line treatment of metastatic breast cancer (mBC) has led to them being widely adopted in this setting. A systematic review of 21 clinical trials in mBC reported a significant improvement in efficacy for taxane-containing regimens compared with nontaxane-containing regimens [4] . In addition, a meta-analysis found greater efficacy of taxane-based combinations than anthracycline-based regimens in first-line mBC [5] . A randomised phase III trial comparing the most commonly used taxanes, docetaxel and paclitaxel, as single agents for mBC found that 3-weekly docetaxel had superior efficacy to 3-weekly paclitaxel but with greater toxicity [6] . Weekly administration of paclitaxel has since been shown to be more effective and less toxic than the 3-weekly schedule, enabling more patients to tolerate this agent and be eligible for taxane-based therapy [7] .
Phase III trials have demonstrated the benefits of paclitaxel and docetaxel in combination with doxorubicin [8, 9] . These findings were later confirmed in the ERASME 3 study [10] , which showed that paclitaxel plus doxorubicin and docetaxel plus doxorubicin had similar efficacy and quality-of-life benefits but differing toxicity profiles. However, anthracyclinerelated cardiotoxicity limits a patient's lifetime cumulative dose, so the widespread use of anthracyclines in the treatment of early breast cancer restricts the use of anthracycline-taxane doublets in the metastatic setting [3] . The benefits of taxanes in mBC have also been shown in combination with other chemotherapies, including gemcitabine and capecitabine [11] [12] [13] , producing greater efficacy than single-agent taxanes.
A meta-analysis of 37 studies has demonstrated that the greater efficacy of combination chemotherapy regimens compared with single agents is accompanied by an increase in toxicity [14] . There is currently no one recommended regimen for the first-line treatment of human epidermal growth factor receptor-2 (HER2)-negative mBC, although anthracyclinebased combinations are the preferred option for patients who have not previously received these agents in the neo/adjuvant setting [3] . Recommendations for patients with anthracyclineresistant disease or high cumulative anthracycline exposure include taxane monotherapy (3-weekly docetaxel, weekly paclitaxel or weekly nanoparticle albumin-bound (nab-) paclitaxel, the first two being the most prevalent) or taxanebased combinations [3] .
Strategies for increasing therapeutic options in mBC may include the development of new taxoid therapies, the reformulation of existing agents and the identification of new efficacious combinations. The novel taxoids XRP6258 and larotaxel have both shown activity in taxane-resistant mBC (disease relapsing within 12 months of neo/adjuvant taxane therapy or receiving little benefit from first use of a taxane in the metastatic setting) [15, 16] .
Ixabepilone, an epothilone recently approved by the Food and Drug Administration for the treatment of mBC unresponsive to currently available chemotherapies, is another treatment option as a monotherapy for second-line use [17] . New formulations of taxanes have also demonstrated efficacy and may have tolerability benefits that could improve outcomes over standard docetaxel or paclitaxel, by increasing or maintaining dose intensity. Nab-paclitaxel, for example, has demonstrated higher objective response rates (ORRs) and longer time to progression (TTP) than standard polyethylated castor oil-based paclitaxel [18] . Additionally, nab-paclitaxel has a shorter administration time than the standard formulation and does not require corticosteroid premedication to prevent hypersensitivity reactions. A phase II study has shown weekly nab-paclitaxel to have superior efficacy and safety to 3-weekly docetaxel in the first-line treatment of mBC, with an increase in progression-free survival (PFS) of >5 months [19] . Formulation of paclitaxel in polymeric micelles (Genexol-PM) has also been shown to have clinical activity in mBC [20] . Combination with cyclosporin increases the bioavailability of orally administered paclitaxel and may provide a new convenient therapeutic option [21] . In addition to these novel formulations, new combination partners for more established agents are being sought.
Improvements in our understanding of the molecular pathogenesis of tumours have led to the development of biological therapies, some of which have been combined with taxanes in mBC. Inhibitors of members of the epidermal growth factor receptor (EGFR) family include the dual EGFR and HER2 inhibitor lapatinib and trastuzumab, a humanised mAb against HER2. In a phase III study of paclitaxel combined with lapatinib or placebo, the lapatinib arm showed significant efficacy improvements in HER2-positive disease compared with the placebo arm [22] . In a phase III trial, the addition of trastuzumab to chemotherapy (anthracycline plus cyclophosphamide or single-agent paclitaxel) in patients with HER2-positive disease demonstrated improved efficacy [23] . The addition of trastuzumab to docetaxel was also more efficacious than docetaxel alone in a phase II study [24] . Firstline trastuzumab alone or in combination with taxane therapy and maintenance trastuzumab monotherapy is now standard of care for patients with HER2-positive mBC [1] .
the role of antiangiogenic agents in the treatment of mBC Tumour growth and development are dependent on angiogenesis [25] . Vascular endothelial growth factor (VEGF) is a key pro-angiogenic mediator, overexpressed in many tumours and associated with poor prognosis, making it an attractive target for the development of a biological therapy [26] . Agents that target angiogenesis, a process essential for all types of solid tumour, have the potential to benefit all breast cancer patients, regardless of patient and/or disease characteristics. Inhibition of VEGF signalling has been shown to provide control of tumour growth and metastasis by causing regression of tumour vasculature, normalisation of surviving vasculature and inhibition of further tumour angiogenesis [27, 28] .
Bevacizumab is a humanised mAb that specifically binds VEGF, preventing it from interacting with receptors on vascular endothelial cells and thereby inhibiting its pro-angiogenic effects [29, 30] . Bevacizumab is currently approved for the treatment of metastatic colorectal cancer, non-small-cell lung cancer, renal cell cancer and mBC [31, 32] . It is also approved in the United States for the treatment of recurrent glioblastoma multiforme [31] ; the EU licence is anticipated in 2010. Other methods of inhibiting angiogenesis through the VEGF pathway include small-molecule tyrosine kinase inhibitors (TKIs; e.g. sunitinib, sorafenib, axitinib) and a soluble VEGF receptor (VEGF-Trap). Circulating VEGF binds to VEGF-Trap, reducing the free VEGF available to activate cell surface receptors. TKIs inhibit downstream signalling from the VEGF receptor after binding of the ligand and are relatively nonspecific inhibitors of receptor tyrosine kinase activity. For example, in addition to VEGF receptor-1, -2 and -3, targets of sunitinib include platelet-derived growth factor receptor-a and -b, c-Kit, FMS-like tyrosine kinase 3 (Flt-3), colony-stimulating factor-1 receptor and the rearranged during transfection protooncogene [33, 34] .
bevacizumab in combination with taxanes
There is preclinical evidence that taxanes have antiangiogenic, as well as cytotoxic, effects, indicating possible synergies with agents targeting VEGF [35, 36] . This has generated much interest in the combination of antiangiogenic biological agents with taxanes. At present, bevacizumab is the most advanced anti-VEGF agent in development, with clinical data available from three phase III studies in patients with mBC [37] [38] [39] [40] [41] .
efficacy of bevacizumab combined with taxanes in mBC bevacizumab in combination with paclitaxel. E2100 was a phase III trial designed to compare the efficacy of bevacizumab plus paclitaxel with paclitaxel alone in the first-line treatment of locally recurrent (LR) breast cancer or mBC [37, 38] . Data from this trial supported regulatory approval of bevacizumab plus paclitaxel in Europe and the United States [31, 32] . Weekly paclitaxel (90 mg/m 2 , weeks 1-3 every 4 weeks) was administered to 722 patients, either alone or with bevacizumab (10 mg/kg every 2 weeks). Treatment was continued until disease progression or unacceptable toxicity. The combination of bevacizumab with paclitaxel significantly increased investigator-assessed PFS compared with paclitaxel alone [median 11.4 versus 5.8 months; hazard ratio (HR) = 0.42; P < 0.0001] and had a significant effect on ORR (48% versus 23%, P < 0.0001) [38, 42] . A blinded independent review of tumour assessments in E2100 confirmed the significant improvement in PFS (median 11.3 versus 5.8 months; HR = 0.48; P < 0.0001) [38] and ORR (50% versus 22%, P < 0.0001) ( Table 1 ) [42] . One-year survival was significantly higher with bevacizumab (median 81.4% versus 74%; P = 0.017; Table 1 ) and there was a trend towards improved overall survival (OS) (26.5 versus 24.8 months; HR = 0.87; P = 0.14) compared with paclitaxel alone [39] .
bevacizumab in combination with docetaxel. The combination of bevacizumab with docetaxel as first-line therapy for women with LR breast cancer or mBC was evaluated in the phase III AVastin And DOcetaxel (AVADO) trial [40] . A total of 736 patients received docetaxel (100 mg/m 2 ) in combination with either bevacizumab (at 7.5 or 15 mg/kg) or placebo every 3 weeks. Treatment with bevacizumab or placebo was continued until disease progression or unacceptable toxicity; up to nine cycles of docetaxel were allowed.
The primary analysis for AVADO was carried out after a prespecified number of PFS events and demonstrated significant PFS improvement in both bevacizumab arms relative to placebo [43] . In the latest analysis of data from this trial, carried out after a median follow-up of 25 months, PFS was superior in both bevacizumab treatment arms compared with placebo and results for the 15 mg/kg arm were more favourable than for the 7.5 mg/kg arm [median 10.0 months (15 mg/kg), HR = 0.67; P = 0.0002 and 9.0 months (7.5 mg/kg), HR = 0.80; P = 0.0450 versus 8.1 months; Table 1 ] [40] . As a result, the dose equivalent of 5 mg/kg/week of bevacizumab was given regulatory approval in combination with docetaxel in the EU.
other studies of bevacizumab in combination with taxanes. The ATHENA study evaluated bevacizumab in combination with first-line chemotherapy for mBC in a broad community-based population, reflecting general oncology practice [44] . This open-label multicentre study, which enrolled >2000 patients, is the largest study population of patients with LR breast cancer or mBC receiving bevacizumab with chemotherapy. Patients received bevacizumab 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks in combination with the physician's choice of taxane-based therapy or other (non-anthracycline containing) standard-of-care regimen. A preliminary efficacy analysis revealed a median TTP of 9.5 months; median OS has not yet been reached [44] .
The RIBBON-1 phase III study of 1237 patients has also demonstrated the efficacy and safety of combining bevacizumab with first-line chemotherapy for LR breast cancer or mBC, including taxanes [41] . Patients received placebo or bevacizumab 15 mg/kg every 3 weeks in combination with the physician's choice of taxanes, an anthracycline-based regimen or capecitabine. Irrespective of the chemotherapy partner, the combination with bevacizumab showed significantly better efficacy than chemotherapy plus placebo [41] .
bevacizumab and taxane activity in patient subgroups. Evidence from phase III clinical trials indicates that bevacizumab is effective across a broad range of patient subgroups (Figure 1) . In a retrospective analysis of the AVADO study, bevacizumab plus docetaxel was well tolerated in elderly patients (aged ‡65 years) with mBC [45] . The magnitude of the benefit provided by bevacizumab was similar to that in the overall study population. An analysis of patients >70 years of age in ATHENA also showed that treatment with bevacizumab is active and feasible in elderly patients [46] .
Bevacizumab is the first antiangiogenic agent that has been shown to be effective in patients with HER2-negative breast Patients were censored if they had started nonprotocol therapy before disease progression (data by Independent Review Facility for E2100; data by investigator for AVADO). b P values are of an exploratory nature. c Patients with measurable disease at baseline: E2100 (paclitaxel, n = 243; bevacizumab + paclitaxel, n = 229); AVADO (placebo + docetaxel, n = 207; 7.5 mg/ kg bevacizumab + docetaxel, n = 201; 15 mg/kg bevacizumab + docetaxel, n = 206). q2w, every 2 weeks; q3w, every 3 weeks; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ORR, objective response rate.
cancer. This is likely to be important for the 'triple-negative' patient subgroup, who demonstrate a more aggressive form of the disease and for whom there was previously no biological therapy available. In the AVADO and E2100 studies, those patients receiving bevacizumab in the triple-negative subgroup achieved equivalent PFS benefit to the overall study population [38, 40] . PFS increases in both E2100 and AVADO were also seen regardless of prognostic characteristics such as disease-free interval and the number of metastatic sites ( Figure 1 ) [38, 40] . Another new class of agent, the poly-ADP ribose polymerase inhibitor, has recently also shown promise in the triple-negative patient subgroup [47] ; a phase III study is now underway. Bevacizumab in combination with docetaxel or paclitaxel showed a consistent PFS benefit regardless of whether adjuvant chemotherapy had been received, including those previously exposed to taxanes (Figure 1 ) [38, 40] . In AVADO, 17% of patients in the 15 mg/kg bevacizumab treatment arm and 15% of patients in the placebo arm had received taxane-based adjuvant therapy and the study eligibility criteria specified that such patients had to have been in remission for a minimum of 12 months after adjuvant therapy.
To date, despite extensive research, no biomarkers have been identified that definitively predict patients who might obtain most benefit from bevacizumab therapy or determine which patients might be at risk of progression while receiving bevacizumab [48] [49] [50] [51] [52] .
no increased tumour growth following withdrawal of VEGF inhibition. Recently, concerns have been raised from preclinical studies about the potential for increased tumour growth following withdrawal of VEGF inhibitors [53, 54] . These studies used either small-molecule TKIs or antibodies against VEGF receptor-2 and may not reflect the clinical situation with bevacizumab, which has a different mechanism of action. Exploratory analyses carried out on data from AVADO showed no evidence for an increase in tumour malignant potential in patients receiving bevacizumab therapy [55] . PFS was longer after discontinuation of bevacizumab than after discontinuation of placebo and mortality rates following discontinuation were similar. Fewer patients receiving bevacizumab had new metastatic lesions at disease progression than those in the placebo arm, indicating that metastatic spread was not increased. Figure 1 . PFS benefit was consistent across patient subgroups in two phase III trials in mBC [38, 40] . PFS, progression-free survival; mBC, metastatic breast cancer; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor-2; q2w, every 2 weeks; q3w, every 3 weeks.
safety and tolerability of bevacizumab in combination with taxanes in mBC
The side-effect profile of bevacizumab is well established and generally manageable and is known to differ considerably from those of conventional chemotherapy agents [56] . Adverse events associated with bevacizumab therapy include hypertension, gastrointestinal perforations, arterial or venous thromboembolic events, cardiotoxicity, fistula/abscess, bleeding events, proteinuria or wound-healing complications. However, the more frequently seen adverse events are mild to moderate in severity, responsive to standard treatment interventions and do not lead to treatment cessation [32] . Excluding pregnant women and those at risk of hypersensitivity reactions, bevacizumab is not contraindicated in any subgroup of patients, although caution should be exercised when treating certain patients, such as those with clinically significant cardiovascular disease or a history of arterial thromboembolism [32] . Pre-existing hypertension should be controlled before commencing bevacizumab therapy. It is recommended that treatment with bevacizumab is permanently discontinued in patients who experience gastrointestinal perforation, arterial thromboembolism, significant hypertension that cannot be medically controlled, grade 3-4 bleeding or grade 4 fistula (or any tracheoesophageal fistula), proteinuria or pulmonary embolism [32] .
Safety data for bevacizumab in combination with taxanes are available from E2100 [37] , AVADO [40] and ATHENA [44] ( Tables 2 and 3) . Generally, the combination of bevacizumab with taxanes has no impact on the known toxic effects of the taxane used. The frequencies of adverse events of special interest with bevacizumab were consistent across these large phase III trials, with the exception of hypertension and proteinuria, which were higher in the bevacizumab treatment arm of E2100 than in AVADO ( Table 2 ). The reason for the differences between studies is unknown but there may have been several contributing factors. The double-blinded placebocontrolled nature of the AVADO study is likely to have reduced reporting bias, compared with the open-label E2100 study. Importantly, in AVADO, gastrointestinal perforations, arterial and venous thromboembolic events, congestive heart failure, fistula/abscess, bleeding events, proteinuria and wound-healing complications were not more common in the bevacizumab arms than the placebo arm [40] . Further, toxic effects particular to antiangiogenic agents (namely hypertension, bleeding and thrombosis) occurred less frequently than in the pivotal trials of bevacizumab in colorectal and non-small-cell lung cancer [57, 58] . The lower rate of hypertension seen in AVADO was confirmed by the results from the ATHENA safety trial [43] .
Some differences in reported toxicity between studies may also reflect the choice of taxane, consistent with the known side-effect profiles of these agents. For example, sensory neuropathy was reported more often with paclitaxel in E2100, whereas neutropenia was more common with docetaxel in AVADO (Table 3 ) [37, 40] . In addition, differences in reporting requirements for the two study arms in E2100 may have led to a greater number of adverse events being collected in the bevacizumab arm versus the control arm, preventing a valid comparison between arms. The duration of chemotherapy may also have impacted on the incidence of chemotherapy-related adverse events. In E2100, patients received paclitaxel until disease progression, thereby increasing paclitaxel exposure in the bevacizumab arm, where progression occurred later. The median duration of paclitaxel treatment in this study was 5.1 months in patients treated with paclitaxel alone Table 2 . Clinical trials of bevacizumab in combination with taxanes: safety summary O'Shaughnessy et al. [12] Chan et al. [13] Albain et al. [11] Nabholtz et al. (n = 261) q4w, every 4 weeks; q3w, every 3 weeks; NR, not reported; q2w, every 2 weeks. and 7.1 months in patients treated with combined therapy [37] . This may account for the apparent increase in levels of toxic effects such as sensory neuropathy in the bevacizumab study arm.
bevacizumab in combination with taxane: a less toxic alternative to chemotherapy doublets?
Meta-analyses have demonstrated that combination chemotherapy regimens have greater efficacy than single agents but with a corresponding increase in toxicity [14] . In phase III studies, the toxicity profiles of bevacizumab and taxanes did not overlap and bevacizumab-taxane doublets were generally well tolerated [37, 40] . Bevacizumab in combination with taxane chemotherapy may therefore have lower toxicity than chemotherapy doublet regimens, particularly for haematological toxic effects such as neutropenia and anaemia (Table 3) . It is important to note that these trials demonstrated not only that there was no increase in the rates of treatmentrelated mortality with the inclusion of bevacizumab but also that events such as fatigue, diarrhoea, vomiting, nausea, stomatitis/mucositis, or hand-foot syndrome were not substantially increased. Bevacizumab-taxane doublets were shown to produce superior PFS and response rates to single-agent taxanes [38, 40] . Comparing the PFS benefits and response rates obtained in E2100 and AVADO with those reported in the medical literature for taxane-based regimens reveals at least comparable efficacy for bevacizumab-taxane doublets and chemotherapy-taxane doublets (and taxane-trastuzumab doublets in the HER2-positive population) (Figure 2 ) [9, [11] [12] [13] 59] .
The improvement in PFS has not been associated with an OS advantage with the use of bevacizumab and a taxane. Although OS is regarded as a 'gold standard' of efficacy, the availability of other agents to treat patients with mBC impacts on the difficulty in demonstrating a significant OS benefit from the initial regimen used.
Overall, these data indicate that since there is no contraindication or safety issue when combining bevacizumab with taxanes, this is a valid treatment option, with advantages over taxane doublets.
future directions with bevacizumab
A phase I-II study has demonstrated the feasibility of dual inhibition of the HER2 and VEGF pathways by combining bevacizumab with trastuzumab in HER2-positive mBC [60] . This is under further evaluation in two phase III studies, AVEREL and E1105. Data for bevacizumab in hormone receptor-positive disease will be generated from the Grupo Español de Investigació n del Cáncer de Mama/2006-11 and CALGB (Cancer and Leukaemia Group B) 40503 studies (Table 4 ). Following strong clinical evidence of the benefits of bevacizumab in the first-line setting, a further phase III trial, RIBBON-2, has evaluated the efficacy and safety of bevacizumab in combination with taxanes or other agents (capecitabine, gemcitabine or vinorelbine) in the second-line treatment of mBC (Table 4) [61] . These data were positive and demonstrated that the addition of bevacizumab to chemotherapies commonly used in second-line treatment of mBC achieved a 10% increase in ORR and significantly improved PFS (P = 0.0072; HR = 0.775) versus chemotherapy plus placebo. The adverse event profile of bevacizumab in the overall study population and across the chemotherapy cohorts was consistent with previous observations [62] .
Clinical studies are also ongoing to investigate bevacizumab in the adjuvant and neoadjuvant settings. VEGF may be the predominant pro-angiogenic factor expressed at early disease stages, while other angiogenic factors become more important in more advanced disease [63] . Even greater benefit could, therefore, be obtained when bevacizumab is used in earlier stage disease, compared with the metastatic setting [64] . Ongoing trials of bevacizumab in combination with taxanes or other agents in the adjuvant setting include BEATRICE (triplenegative disease), E5103 (HER2-negative disease) and BETH (HER2-positive disease) ( Table 4 ). The NSABP B-40 and GeparQuinto trials are both investigating bevacizumab in the neoadjuvant setting (Table 4) .
conclusions
Bevacizumab, an mAb against VEGF, inhibits tumour angiogenesis and has demonstrated efficacy in the first-line treatment of patients with mBC in combination with taxanes. Bevacizumab has a well-established and manageable side-effect profile and is generally well tolerated when combined with taxanes, with limited incremental toxicity. There are no specific co-morbidities that exclude patients from therapy with bevacizumab, but certain subgroups of patients, such as those with a history of cardiovascular disease or arterial thromboembolism, should be monitored more closely during treatment. Unlike targeted therapies such as trastuzumab, there is no identifiable marker to predict likelihood of response to bevacizumab and patient selection on the basis of tumour characteristics is not possible. However, the combination of bevacizumab with taxanes has demonstrated greater efficacy than single-agent taxane therapy and should be considered an option in the first-line treatment of patients with HER2-negative mBC who have adequate performance status and a disease burden such that taxane-containing therapy is indicated. Such combinations are an alternative to chemotherapy doublet regimens, with equivalent efficacy and potentially lower toxicity.
Additional trials to investigate the safety and efficacy of bevacizumab in combination with taxanes in the treatment of early breast cancer, in patients with hormone receptor-or HER2-positive disease or in the second-line treatment of mBC are ongoing and results are awaited with interest. The authors would like to acknowledge medical writing support by Jane Blackburn of Gardiner-Caldwell Communications.
